We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
21 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Vafseo (vadadustat) was approved for the treatment of anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 450 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 150 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 300 mg tablet blister pack.
-
Designation or determinationProvisional determination
-
-
Prescription medicine decision summaryVafseo (vadadustat) is approved to treat anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
-
Prescription medicine registrationActive ingredients: vadadustat.
-
Australian public assessment report (AusPar)AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
-
Australian public assessment report (AusPar)For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma